These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

857 related items for PubMed ID: 30339790

  • 1. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
    Chalmers SA, Glynn E, Garcia SJ, Panzenbeck M, Pelletier J, Dimock J, Seccareccia E, Bosanac T, Khalil S, Harcken C, Webb D, Nabozny G, Fine JS, Souza D, Klein E, Herlitz L, Ramanujam M, Putterman C.
    Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
    [Abstract] [Full Text] [Related]

  • 2. Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis.
    Katewa A, Wang Y, Hackney JA, Huang T, Suto E, Ramamoorthi N, Austin CD, Bremer M, Chen JZ, Crawford JJ, Currie KS, Blomgren P, DeVoss J, DiPaolo JA, Hau J, Johnson A, Lesch J, DeForge LE, Lin Z, Liimatta M, Lubach JW, McVay S, Modrusan Z, Nguyen A, Poon C, Wang J, Liu L, Lee WP, Wong H, Young WB, Townsend MJ, Reif K.
    JCI Insight; 2017 Apr 06; 2(7):e90111. PubMed ID: 28405610
    [Abstract] [Full Text] [Related]

  • 3. Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.
    Chalmers SA, Wen J, Doerner J, Stock A, Cuda CM, Makinde HM, Perlman H, Bosanac T, Webb D, Nabozny G, Fine JS, Klein E, Ramanujam M, Putterman C.
    Arthritis Res Ther; 2018 Jan 25; 20(1):10. PubMed ID: 29370834
    [Abstract] [Full Text] [Related]

  • 4. HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus.
    Kim YY, Park KT, Jang SY, Lee KH, Byun JY, Suh KH, Lee YM, Kim YH, Hwang KW.
    Arthritis Res Ther; 2017 Sep 26; 19(1):211. PubMed ID: 28950886
    [Abstract] [Full Text] [Related]

  • 5. BTK inhibition modulates multiple immune cell populations involved in the pathogenesis of immune mediated nephritis.
    Chalmers SA, Garcia SJ, Webb D, Herlitz L, Fine J, Klein E, Ramanujam M, Putterman C.
    Clin Immunol; 2021 Feb 26; 223():108640. PubMed ID: 33296718
    [Abstract] [Full Text] [Related]

  • 6. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
    Keil A, Hall SR, Körner M, Herrmann M, Schmid RA, Frese S.
    Arthritis Res Ther; 2016 Oct 22; 18(1):243. PubMed ID: 27770825
    [Abstract] [Full Text] [Related]

  • 7. Amiselimod (MT-1303), a Novel Sphingosine 1-Phosphate Receptor-1 Modulator, Potently Inhibits the Progression of Lupus Nephritis in Two Murine SLE Models.
    Sugahara K, Maeda Y, Shimano K, Murase M, Mochiduki S, Takemoto K, Kakimoto T, Utsumi H, Oshita K, Kataoka H.
    J Immunol Res; 2019 Oct 22; 2019():5821589. PubMed ID: 31930150
    [Abstract] [Full Text] [Related]

  • 8. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus.
    Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, Galle PR, Schwarting A.
    J Rheumatol; 2010 Jan 22; 37(1):60-70. PubMed ID: 19955044
    [Abstract] [Full Text] [Related]

  • 9. Function of the Th17/interleukin-17A immune response in murine lupus nephritis.
    Schmidt T, Paust HJ, Krebs CF, Turner JE, Kaffke A, Bennstein SB, Koyro T, Peters A, Velden J, Hünemörder S, Haag F, Steinmetz OM, Mittrücker HW, Stahl RA, Panzer U.
    Arthritis Rheumatol; 2015 Feb 22; 67(2):475-87. PubMed ID: 25385550
    [Abstract] [Full Text] [Related]

  • 10. Activation-induced deaminase-deficient MRL/lpr mice secrete high levels of protective antibodies against lupus nephritis.
    Jiang C, Zhao ML, Scearce RM, Diaz M.
    Arthritis Rheum; 2011 Apr 22; 63(4):1086-96. PubMed ID: 21225690
    [Abstract] [Full Text] [Related]

  • 11. Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.
    Rankin AL, Seth N, Keegan S, Andreyeva T, Cook TA, Edmonds J, Mathialagan N, Benson MJ, Syed J, Zhan Y, Benoit SE, Miyashiro JS, Wood N, Mohan S, Peeva E, Ramaiah SK, Messing D, Homer BL, Dunussi-Joannopoulos K, Nickerson-Nutter CL, Schnute ME, Douhan J.
    J Immunol; 2013 Nov 01; 191(9):4540-50. PubMed ID: 24068666
    [Abstract] [Full Text] [Related]

  • 12. Regulation of basement membrane-reactive B cells in BXSB, (NZBxNZW)F1, NZB, and MRL/lpr lupus mice.
    Clark AG, Fan Q, Brady GF, Mackin KM, Coffman ED, Weston ML, Foster MH.
    Autoimmunity; 2013 May 01; 46(3):188-204. PubMed ID: 23157336
    [Abstract] [Full Text] [Related]

  • 13. Intermittent Fasting Aggravates Lupus Nephritis through Increasing Survival and Autophagy of Antibody Secreting Cells in MRL/lpr Mice.
    Hong SM, Lee J, Jang SG, Song Y, Kim M, Lee J, Cho ML, Kwok SK, Park SH.
    Int J Mol Sci; 2020 Nov 11; 21(22):. PubMed ID: 33187196
    [Abstract] [Full Text] [Related]

  • 14. Suppression of glomerulonephritis in lupus-prone NZB × NZW mice by RN486, a selective inhibitor of Bruton's tyrosine kinase.
    Mina-Osorio P, LaStant J, Keirstead N, Whittard T, Ayala J, Stefanova S, Garrido R, Dimaano N, Hilton H, Giron M, Lau KY, Hang J, Postelnek J, Kim Y, Min S, Patel A, Woods J, Ramanujam M, DeMartino J, Narula S, Xu D.
    Arthritis Rheum; 2013 Sep 11; 65(9):2380-91. PubMed ID: 23754328
    [Abstract] [Full Text] [Related]

  • 15. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.
    Steinmetz OM, Turner JE, Paust HJ, Lindner M, Peters A, Heiss K, Velden J, Hopfer H, Fehr S, Krieger T, Meyer-Schwesinger C, Meyer TN, Helmchen U, Mittrücker HW, Stahl RA, Panzer U.
    J Immunol; 2009 Oct 01; 183(7):4693-704. PubMed ID: 19734217
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of EZH2 Ameliorates Lupus-Like Disease in MRL/lpr Mice.
    Rohraff DM, He Y, Farkash EA, Schonfeld M, Tsou PS, Sawalha AH.
    Arthritis Rheumatol; 2019 Oct 01; 71(10):1681-1690. PubMed ID: 31106974
    [Abstract] [Full Text] [Related]

  • 17. NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus.
    Brightbill HD, Suto E, Blaquiere N, Ramamoorthi N, Sujatha-Bhaskar S, Gogol EB, Castanedo GM, Jackson BT, Kwon YC, Haller S, Lesch J, Bents K, Everett C, Kohli PB, Linge S, Christian L, Barrett K, Jaochico A, Berezhkovskiy LM, Fan PW, Modrusan Z, Veliz K, Townsend MJ, DeVoss J, Johnson AR, Godemann R, Lee WP, Austin CD, McKenzie BS, Hackney JA, Crawford JJ, Staben ST, Alaoui Ismaili MH, Wu LC, Ghilardi N.
    Nat Commun; 2018 Jan 12; 9(1):179. PubMed ID: 29330524
    [Abstract] [Full Text] [Related]

  • 18. CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.
    Moser K, Kalies K, Szyska M, Humrich JY, Amann K, Manz RA.
    Arthritis Rheum; 2012 Apr 12; 64(4):1237-46. PubMed ID: 22006377
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of the alternative complement pathway by antisense oligonucleotides targeting complement factor B improves lupus nephritis in mice.
    Grossman TR, Hettrick LA, Johnson RB, Hung G, Peralta R, Watt A, Henry SP, Adamson P, Monia BP, McCaleb ML.
    Immunobiology; 2016 Jun 12; 221(6):701-8. PubMed ID: 26307001
    [Abstract] [Full Text] [Related]

  • 20. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice.
    Lichtnekert J, Rupanagudi KV, Kulkarni OP, Darisipudi MN, Allam R, Anders HJ.
    J Immunol; 2011 Sep 15; 187(6):3413-21. PubMed ID: 21849682
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.